Alexion Pharm Inc (ALXN) 123.57 $ALXN
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 17, 8:30PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
ALXN: 123.57 (+2.16)
Alexion Pharmaceuticals Falls 1.62% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 17, 12:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.80 to a high of $127.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $127.20 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.57 (+2.16)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 233.51 (+4.96), BIIB: 238.62 (+4.02), MDT: 85.77 (+1.51), ALXN: 123.57 (+2.16), XOM: 91.80 (+0.63), BMY: 72.64 (+0.33), CVX: 104.44 (+2.15)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 123.57 (+2.16)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), AEGR: 1.67 (+0.11), ACOR: 26.31 (+1.04)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 238.62 (+4.02), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), REGN: 357.14 (+5.22), CELG: 100.66 (+1.43)
Company News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Companies in the News are: HTZ,ALXN,VRX,UNFI
VRX: 22.25 (+0.61), UNFI: 45.74 (+0.75), HTZ: 11.86 (+0.52), ALXN: 123.57 (+2.16)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
PR Newswire - Wed Jun 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. ("Alexion" or "the Company" (NASDAQ: ALXN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
ALXN: 123.57 (+2.16)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Tue Jun 07, 5:20PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company" (Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
ALXN: 123.57 (+2.16)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 22.25 (+0.61), UNFI: 45.74 (+0.75), ALXN: 123.57 (+2.16), ZG: 35.50 (+0.77), CVX: 104.44 (+2.15), VZ: 54.67 (+0.64), RL: 97.25 (+0.84), VRX.TO: 28.34 (+0.61), Z: 35.38 (+0.79)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN
BusinessWire - Tue Jun 07, 12:04PM CDT
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. ("Alexion Pharmaceuticals" or the "Company" (NASDAQ:ALXN) concerning possible violations of federal securities laws.
ALXN: 123.57 (+2.16)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 10.88% Sell Off
Comtex SmarTrend(R) - Tue Jun 07, 11:50AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $136.14 to a high of $140.75. Yesterday, the shares fell 10.9%, which took the trading range below the 3-day low of $150.60 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.57 (+2.16)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ALXN: 123.57 (+2.16), BMY: 72.64 (+0.33)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN
PR Newswire - Tue Jun 07, 10:32AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the Company) (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
ALXN: 123.57 (+2.16)
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris(R)) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
BusinessWire - Mon Jun 06, 3:01PM CDT
--- Detailed Results to be Presented at the 14th International Congress on Neuromuscular Diseases (ICNMD) July 7 in Toronto-
ALXN: 123.57 (+2.16)
Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ALXN: 123.57 (+2.16), BMY: 72.64 (+0.33)
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 17, 8:30PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. ALXN: 123.57 (+2.16)
Alexion Pharmaceuticals Falls 1.62% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jun 17, 12:18PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $124.80 to a high of $127.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $127.20 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.57 (+2.16)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 233.51 (+4.96), BIIB: 238.62 (+4.02), MDT: 85.77 (+1.51), ALXN: 123.57 (+2.16), XOM: 91.80 (+0.63), BMY: 72.64 (+0.33), CVX: 104.44 (+2.15)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
BusinessWire - Fri Jun 10, 1:30AM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells).(1) In this study, once-monthly dosing of ALXN1210 achieved rapid and sustained reductions in mean levels of lactate dehydrogenase (LDH), a marker of hemolysis, in 100 percent of treated patients, which were observed through up to five once-monthly dosing intervals. Researchers also reported that, at this time, 80 percent of patients who required at least 1 blood transfusion in the 12 months prior to treatment with ALXN1210 did not require transfusions while on treatment.(2) These findings were presented in a late-breaking poster at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.
ALXN: 123.57 (+2.16)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), AEGR: 1.67 (+0.11), ACOR: 26.31 (+1.04)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 238.62 (+4.02), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), REGN: 357.14 (+5.22), CELG: 100.66 (+1.43)
Company News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Companies in the News are: HTZ,ALXN,VRX,UNFI
VRX: 22.25 (+0.61), UNFI: 45.74 (+0.75), HTZ: 11.86 (+0.52), ALXN: 123.57 (+2.16)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)
PR Newswire - Wed Jun 08, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. ("Alexion" or "the Company"
(NASDAQ: ALXN). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. ALXN: 123.57 (+2.16)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm
BusinessWire - Tue Jun 07, 5:20PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company"
(Nasdaq: ALXN). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. ALXN: 123.57 (+2.16)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 22.25 (+0.61), UNFI: 45.74 (+0.75), ALXN: 123.57 (+2.16), ZG: 35.50 (+0.77), CVX: 104.44 (+2.15), VZ: 54.67 (+0.64), RL: 97.25 (+0.84), VRX.TO: 28.34 (+0.61), Z: 35.38 (+0.79)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Alexion Pharmaceuticals, Inc. -- ALXN
BusinessWire - Tue Jun 07, 12:04PM CDT
Levi & Korsinsky announces it has commenced an investigation of Alexion Pharmaceuticals, Inc. ("Alexion Pharmaceuticals" or the "Company"
(NASDAQ:ALXN) concerning possible violations of federal securities laws. ALXN: 123.57 (+2.16)
Look for Shares of Alexion Pharmaceuticals to Potentially Rebound after Yesterday's 10.88% Sell Off
Comtex SmarTrend(R) - Tue Jun 07, 11:50AM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $136.14 to a high of $140.75. Yesterday, the shares fell 10.9%, which took the trading range below the 3-day low of $150.60 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.57 (+2.16)
Alexion's Soliris Misses Phase III Primary Efficacy Endpoint
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:49AM CDT
Alexion Pharmaceuticals' (ALXN) Soliris failed to hit the phase III primary endpoint in patients suffering from refractory generalized myasthenia gravis.
ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ALXN: 123.57 (+2.16), BMY: 72.64 (+0.33)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN
PR Newswire - Tue Jun 07, 10:32AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the Company) (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
ALXN: 123.57 (+2.16)
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris(R)) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
BusinessWire - Mon Jun 06, 3:01PM CDT
--- Detailed Results to be Presented at the 14th International Congress on Neuromuscular Diseases (ICNMD) July 7 in Toronto-
ALXN: 123.57 (+2.16)
Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 9:15AM CDT
Alexion Pharmaceuticals (ALXN) announced that ALXN1210 received orphan drug status in the EU for paroxysmal nocturnal hemoglobinuria.
ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ALXN: 123.57 (+2.16), BMY: 72.64 (+0.33)
